
AC Immune (ACIU) Stock Forecast & Price Target
AC Immune (ACIU) Analyst Ratings
Bulls say
AC Immune is a clinical stage biopharmaceutical company that specializes in Precision Medicine for neurodegenerative diseases, with a focus on discovering and developing therapies targeting misfolded proteins. The company has a diverse pipeline with promising programs, such as ACI-35.030 and ACI-7104.056, which have a 35% and 25% probability of success, respectively. With a strong financial position and upcoming milestone payments, AC Immune is well-positioned for future growth and potential success in the neurodegenerative disease market.
Bears say
AC Immune is a clinical-stage biopharmaceutical company that focuses on developing precision medicine for neurodegenerative diseases, with a significant focus on targeting misfolded proteins. While the company has multiple programs in its pipeline, including promising data for its ACI-24 vaccine and positive results from its PD program, there is no guarantee that these will translate into successful treatments. Additionally, the company's financials may be negatively affected by the high costs of clinical trials and the potential for setbacks or delays in the development process.
This aggregate rating is based on analysts' research of AC Immune and is not a guaranteed prediction by Public.com or investment advice.
AC Immune (ACIU) Analyst Forecast & Price Prediction
Start investing in AC Immune (ACIU)
Order type
Buy in
Order amount
Est. shares
0 shares